Opportunity ID: 328858

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-295
Funding Opportunity Title: Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.394 — Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Aug 28, 2020
Last Updated Date: Sep 23, 2020
Original Closing Date for Applications: Oct 13, 2021
Current Closing Date for Applications: Oct 13, 2021
Archive Date: Nov 18, 2021
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Native American tribal governments (Federally recognized)
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Special district governments
Public housing authorities/Indian housing authorities
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description:

[The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-295.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date
Updated eligibility in accordance with NOT-CA-20-107 Sep 23, 2020
Aug 28, 2020

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-295
Funding Opportunity Title: Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.394 — Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Aug 28, 2020
Last Updated Date: Sep 23, 2020
Original Closing Date for Applications: Oct 13, 2021
Current Closing Date for Applications: Oct 13, 2021
Archive Date: Nov 18, 2021
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Native American tribal governments (Federally recognized)
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Special district governments
Public housing authorities/Indian housing authorities
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description:

[The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-295.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-295
Funding Opportunity Title: Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.394 — Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 28, 2020
Last Updated Date: Aug 28, 2020
Original Closing Date for Applications:
Current Closing Date for Applications: Oct 13, 2021
Archive Date: Nov 18, 2021
Estimated Total Program Funding:
Award Ceiling: $500,000
Award Floor:

Eligibility

Eligible Applicants: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Special district governments
Small businesses
City or township governments
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
State governments
County governments
Independent school districts
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: [The purpose of this PAR is to bring a highly sensitivity imaging technology capable of locating very small (1-3 mm) tumors in vivo to clinical utility. Under this funding opportunity, NCI solicits innovative concepts that propose a path to clinical validation for in vivo intelligent or activated optical fluorescence agents or probes with demonstrated capabilities for detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 106 to 107 cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding background tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence technologies for sensitive cancer detection In Vivo. Clinical translation and validation are the primary goals of the proposed research. Minimal development activity in preparation for clinical validation will be accepted. The bulk of the proposed research must focus on translating improvements to imaging sensitivity to a clinical environment. The goal is to demonstrate that tumor cell aggregations on the order of 1 mm 3 in diameter can be visualized in vivo. This FOA, does not support continued development of novel technologies
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-295.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or before January 24, 2022 PKG00263172 Jan 10, 2021 Jan 24, 2022 View

Package 1

Mandatory forms

328858 RR_SF424_2_0-2.0.pdf

328858 PHS398_CoverPageSupplement_5_0-5.0.pdf

328858 RR_OtherProjectInfo_1_4-1.4.pdf

328858 PerformanceSite_2_0-2.0.pdf

328858 RR_KeyPersonExpanded_2_0-2.0.pdf

328858 PHS398_ResearchPlan_4_0-4.0.pdf

328858 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

328858 RR_Budget_1_4-1.4.pdf

328858 RR_SubawardBudget30_1_4-1.4.pdf

328858 PHS398_ModularBudget_1_2-1.2.pdf

328858 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-10T14:50:20-05:00

Share This Post, Choose Your Platform!

About the Author: